Novocure Limited
A maker of cancer treatments that harness electricity rather than drugs, Novocure produces the Optune device, a wearable system that delivers low-intensity electric fields (called Tumor Treating Fields) to slow tumor growth in adults with glioblastoma, an aggressive brain cancer. It was founded in 2000 by Yoram Palti, a biophysicist who first tested his theory in a lab he set up in the basement of his home in Israel.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Soleus Capital Master Fund, L.P. | 13G/APassive | 9.1% | 10.49M | May 8, 2026 |
| Soleus Capital, LLC | 13G/APassive | 9.1% | 10.49M | May 8, 2026 |
| Soleus Capital Group, LLC | 13G/APassive | 9.1% | 10.49M | May 8, 2026 |
| Soleus Capital Management, L.P. | 13G/APassive | 9.1% | 10.49M | May 8, 2026 |
| Soleus GP, LLC | 13G/APassive | 9.1% | 10.49M | May 8, 2026 |
| Guy Levy | 13G/APassive | 9.1% | 10.49M | May 8, 2026 |
| Vanguard Portfolio Management | 13GPassive | 5.57% | 6.34M | Apr 28, 2026 |
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 26, 2026 |
| Capital World Investors | 13G/APassive | 1.8% | 2.00M | Nov 13, 2025 |
| Capital International Investors | 13G/APassive | 0% | 0 | Jul 7, 2025 |